Fuyuan Pharmaceuticals: Abametapir Atorvastatin Calcium Tablets obtained drug registration certificate.

Fukuyuan Pharmaceuticals announced that the company has recently received the Drug Registration Certificate for the drug Ezetimibe Atorvastatin Calcium Tablets issued by the National Medical Products Administration, approving the production of the drug. Ezetimibe Atorvastatin Calcium Tablets, developed by Organon, was first approved by the FDA for market in May 2013. In September 2023, after approval by the National Medical Products Administration, Ezetimibe Atorvastatin Calcium Tablets was marketed in China. This product is used for hypercholesterolemia and homozygous familial hypercholesterolemia. The company received a notification of acceptance for application on January 8, 2025, and recently obtained approval from the National Medical Products Administration. According to relevant national policies, obtaining the Drug Registration Certificate this time is equivalent to passing the consistency evaluation.